Skip to main navigation Skip to main content Skip to page footer

Academic Clinical Research in the Context of Rare Diseases – Interview with Prof. Dr. med. Wolfgang Bethge

In the EU, a disease is considered rare if it affects no more than 5 in 10,000 people. Academic clinical research is indispensable for developing new therapeutic approaches for rare diseases (RD). On Rare Disease Day, Prof. Dr. Wolfgang Bethge gives us insights into this research.

As director of the ZKS Tübingen, he has been active for many years in clinical research on allogeneic stem cell transplantation and cellular immunotherapies. Among other things, he supports trials of innovative therapeutic approaches such as CAR-T cell therapy. These trials open up new treatment options for people with rare diseases and help to develop effective therapeutic options.

In the interview, Prof. Dr. Wolfgang Bethge talks about the methodological challenges, the role of specialised trial centres and the prospects of innovative therapies for people with rare diseases.
 

Because relatively few patients are available for clinical trials on rare diseases, conducting them is demanding. Which methodological particularities have to be taken into account with small patient cohorts?
 

Clinical trials on rare diseases place high methodological demands, because classic trial designs with large case numbers are usually not feasible. At ZKS Tübingen, we therefore support such trials together with the Institute for Clinical Epidemiology and Applied Biometry (IKEAB) Tübingen from the planning stage, with statistical, methodological and regulatory advice, in order to define suitable endpoints, biomarkers, trial designs and analysis strategies. The aim is to achieve valid, regulatorily robust and patient-relevant results even with small patient cohorts. Adaptive designs, registry data, historical control groups and intra-individual comparisons help here.
 

ZKS Tübingen cooperates, among others, with the Centre for Rare Diseases (ZSE) and is known for its expertise in investigator-initiated trials in the field of rare diseases. What role do specialised trial centres play in the success of trials on RD?
 

Specialized study centers such as the ZKS Tübingen are a key factor in the success of clinical trials for rare diseases. They provide the necessary infrastructure, regulatory expertise, and quality assurance, which are essential, particularly for investigator-initiated studies.

Through close cooperation with the Centre for Rare Diseases (ZSE Tübingen), we can closely interlink clinical expertise, structured diagnostics and trial management. This pooling not only makes it easier to recruit suitable patients across regions but also ensures that trials are conducted efficiently, with quality assurance and in a patient-centred way. Last but not least, specialised centres create trust, among patients, investigators and supervisory authorities, and are therefore a decisive success factor for high-quality trials.
 

With regard to innovative cell and immunotherapies: which developments do you consider particularly promising for clinical research on RD?
 

Highly targeted therapies that address the molecular causes of a disease directly are currently particularly promising. These include cell-based therapies as well as immunotherapies that specifically correct misdirected or inadequate biological processes.

This is particularly relevant for rare diseases, as many of them can be traced back to clearly defined genetic or immunological defects. The increasing precision of these therapies opens up new possibilities for developing clinically effective treatments even for very small patient groups.

For clinical research, however, this also means complex trial protocols and high regulatory requirements. Here we see an important role for the ZKS in transferring innovative therapies safely and systematically into early clinical trials.
 

To what extent are new forms of therapy, such as gene, cell or RNA techniques, relevant?
 

New forms of therapy such as gene, cell or RNA-based approaches have the potential to change the treatment of rare diseases fundamentally. Instead of relieving symptoms, they aim to influence or correct the cause of the disease directly.

Particularly in monogenic diseases, such therapies can achieve long-term or even permanent effects. For clinical research, however, this also brings new challenges, for example regarding trial design, safety assessment and long-term follow-up. Structured clinical trials under specialised conditions are therefore all the more important. These new forms of therapy require special expertise, for example in safety concepts, long-term follow-up and regulatory requirements, which is pooled in specialised trial centres.
 

Is a trend emerging in clinical research on RD in the coming years?
 

Yes, a clear trend towards personalised and molecularly defined treatment strategies is emerging. The boundaries between diagnosis and therapy are increasingly blurring, as genetic and molecular characterisation increasingly influences trial planning.

In addition, international collaborations, platform-based trials, high-quality registry studies and the use of real-world data continue to gain in importance. These developments help to evaluate new therapies more efficiently and faster despite small patient numbers.

The ZKS/KKS of the KKS Network increasingly see their role as a methodological and organisational hub that brings together academic research, clinical expertise and regulatory requirements.
 

What is your central message on the importance of clinical research for rare diseases?
 

For people with rare diseases, clinical research is often the only way to effective therapies. It creates not only new treatment options but also knowledge, visibility and hope for patients who for a long time were hardly considered, especially by the commercially oriented research of pharmaceutical companies. Specialised institutions such as the members of the KKS Network make a decisive contribution by translating innovative research approaches into high-quality and safe clinical trials.

Only through these structured framework conditions can new therapies be developed and integrated into the long-term care of patients with rare diseases.

 

KKSN KKSN